RESUMEN
OBJECTIVES: We aimed to determine in-hospital outcomes, length of hospital stay, and resource utilization in a contemporary cohort of Clostridioides difficile infection (CDI) and vitamin D deficiency (VDD). METHODS: The National Inpatient Sample database for 2016 and 2017 was used for data analysis using International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS) codes to identify the patients with the principal diagnosis of CDI and VDD. We assessed the all-cause in-hospital mortality, morbidity, length of hospital stay (LOS), and total costs between propensity-matched groups of CDI without VDD versus CDI with VDD. RESULTS: We identified 202,234 patients with CDI, 4515 of whom were patients with VDD and 197,719 of whom were without VDD. After propensity matching, there was no difference in the in-hospital mortality between the two groups (odds ratio [OR] 1.5, 95% confidence interval [CI] 0.58-4.3; P = 0.90). CDI with VDD has a higher odds of sepsis (OR 1.6, 95% CI 1.3-1.9; P = 0.0), and peritonitis (OR 1.6, 95% CI 1.4-3.8; P = 0.01). Mean LOS (5.9 ± 1.8 vs 5.4 ± 2, P < 0.01) and mean total charges ($11,500 vs $9971, P < 0.04) were higher in CDI with VDD. The factors affecting the LOS were acute coronary syndrome (P = 0.04), mechanical ventilation (P = 0.03), obesity (P = 0.004), acute kidney injury (P = 0.04), and sepsis (P = 0.05). CONCLUSIONS: In this large cohort in a propensity-matched analysis, VDD does not increase the in-hospital mortality in CDI. VDD increases the odds of complications with a higher LOS and resource utilization. These findings may be clinically relevant to guide clinicians to routinely monitor vitamin D status and supplement in patients at risk of CDI.
Asunto(s)
Infecciones por Clostridium/complicaciones , Deficiencia de Vitamina D/complicaciones , Infecciones por Clostridium/mortalidad , Femenino , Mortalidad Hospitalaria , Hospitalización , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Aceptación de la Atención de Salud/estadística & datos numéricos , Puntaje de Propensión , Estudios Retrospectivos , Resultado del Tratamiento , Estados Unidos , Deficiencia de Vitamina D/mortalidadRESUMEN
Vitamin D is traditionally recognized for its role in bone mineralization but recent observations suggest additional pertinent functions in neuronal biology. The present study examines the rate and pattern of Vitamin D deficiency in the outpatient mental health clinic of a community teaching hospital as well as the vitamin D supplementation practices of outpatient psychiatrists. Participants include 148 consecutive psychiatric outpatients. Individuals with conditions that alter the metabolism of vitamin D were excluded from the study as are those who may be taking medications that influence Vitamin D metabolism. Statistical analysis was performed using the SPSS 25th edition, statistical significance set at p < 0.05. The majority of patients in the study were between 41 and 65 years old (n = 91, 61.5%), African American (n = 120, 81.1%) and female (n = 80, 54.1%). The median level is 23.7 ng/ml. As defined by the Endocrine Society's Clinical Practice Guidelines, 68.2% of the population had insufficient and deficient Vitamin D levels (32.4% and 35.8% respectively), 62.4% of whom were not prescribed any Vitamin D supplementation and of this untreated group, 84% were African Americans. No clinical or demographic characteristics showed any statistical difference in both the "treated" and "not treated groups". Logistic regression did not reveal any significant predictors for Vitamin D deficiency. Vitamin D deficiency remains a significant issue among patients with psychiatric disorders. Our findings show gaps in Vitamin D deficiency treatment and recommend that future studies examine physician prescription practices in light of the racial disparity in Vitamin D deficiency treatment oberved in this study.
Asunto(s)
Servicios Comunitarios de Salud Mental/estadística & datos numéricos , Pacientes Ambulatorios/estadística & datos numéricos , Deficiencia de Vitamina D/epidemiología , Adolescente , Adulto , Negro o Afroamericano/estadística & datos numéricos , Anciano , Estudios de Cohortes , Femenino , Humanos , Masculino , Trastornos Mentales/tratamiento farmacológico , Persona de Mediana Edad , New York , Prevalencia , Estudios Retrospectivos , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/tratamiento farmacológico , Población Blanca/estadística & datos numéricos , Adulto JovenRESUMEN
BACKGROUND: The highest burden of hepatitis C virus (HCV) infection is seen in patients with psychiatric disorders who have been excluded from traditional treatments with Interferon due to treatment-emergent neuropsychiatric adverse effects. The goal of this study is to determine the tolerability, treatment retention, and efficacy of direct-acting antivirals with psychiatric disorders and comorbid substance use disorders in real-life settings. METHODS: This is a retrospective cohort observational study of HCV patients treated with direct-acting antivirals between January 2016 and December 2018. Patients were stratified and sub-stratified based on their psychiatric diagnosis and substance use. The primary assessment was the sustained virologic response at 12 weeks post-treatment (SVR12). RESULTS: Among the 291 patients analyzed, patients with psychiatric diagnosis and non-psychiatric patients made up 51.2% (n = 149) and 48.8% (n = 142) respectively. Majority of the patients included in the study were African-Americans (68.7%, n = 200). Overall, 95.3% (142/149) and 94.4% (134/142) of psychiatric and non-psychiatric patients, respectively, achieved SVR12 and treatment response was similar between the groups (p = 0.72). Among psychiatric patients, only the prior treatment status was identified as a predictor of treatment response (OR 0.153, 95% CI 0.03-0.79; p = 0.05). No statistical difference was observed among the patients with SVR12 based on their primary psychiatric diagnoses or by comorbid substance abuse. CONCLUSION: The results of our study show that direct-acting antiviral treatments are well tolerated in psychiatric patients, and an overwhelming majority of patients achieved SVR12. Our study highlights the need to integrate HCV screening with treatment linkage in psychiatry and primary care practice.